Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2024 Mar 28

PMID 38546390

Authors

Giorgia Maroni

Indira Krishnan

Roberta Alfieri

Valerie A Maymi

Nicole Pandell

Eva Csizmadia

Junyan Zhang

Marla Weetall

Art Branstrom

Giulia Braccini

Eva Cabrera San Millan

Barbara Storti

Ranieri Bizzarri

Olivier Kocher

Daniela S Daniela Sanchez Basseres

Robert S Welner

Maria Cristina Magli

Ivan Merelli

John G Clohessy

Azhar Ali

Daniel G Tenen

Elena Levantini

Affiliations

Soon will be listed here.

Abstract

Significance: Targeting the TME is an attractive strategy for treatment of solid tumors. Here we revealed how EGFR-mutant landscapes are affected at the single-cell resolution level during Unesbulin treatment. This novel drug, by targeting cancer cells and their interactions with crucial TME components, could be envisioned for future therapeutic advancements.

Citing Articles

Personalized Treatment Strategies via Integration of Gene Expression Biomarkers in Molecular Profiling of Laryngeal Cancer.

Maniaci A, Giurdanella G, Chiesa Estomba C, Mauramati S, Bertolin A, Lionello M J Pers Med. 2024; 14(10).

PMID: 39452555 PMC: 11508418. DOI: 10.3390/jpm14101048.

References

Tanaka M, Siemann D . Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment. Cancers (Basel). 2020; 12(7). PMC: 7408754. DOI: 10.3390/cancers12071850. View

Chang L, Lim C, Chang L, Chen K, Shih J, Yu C . Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. Eur J Cancer. 2019; 119:77-86. DOI: 10.1016/j.ejca.2019.06.025. View

OLeary C, Gasper H, Sahin K, Tang M, Kulasinghe A, Adams M . Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals (Basel). 2020; 13(10). PMC: 7600164. DOI: 10.3390/ph13100273. View

Mok T, Wu Y, Ahn M, Garassino M, Kim H, Ramalingam S . Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2016; 376(7):629-640. PMC: 6762027. DOI: 10.1056/NEJMoa1612674. View

Heng T, Painter M . The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol. 2008; 9(10):1091-4. DOI: 10.1038/ni1008-1091. View

Yan Y, Zuo X, Wei D . Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. Stem Cells Transl Med. 2015; 4(9):1033-43. PMC: 4542874. DOI: 10.5966/sctm.2015-0048. View

Klein A, Mazutis L, Akartuna I, Tallapragada N, Veres A, Li V . Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell. 2015; 161(5):1187-1201. PMC: 4441768. DOI: 10.1016/j.cell.2015.04.044. View

Baslan T, Hicks J . Unravelling biology and shifting paradigms in cancer with single-cell sequencing. Nat Rev Cancer. 2017; 17(9):557-569. DOI: 10.1038/nrc.2017.58. View

Dey A, Xiong X, Crim A, Dwivedi S, Mustafi S, Mukherjee P . Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2017; 17(1):39-49. PMC: 5752598. DOI: 10.1158/1535-7163.MCT-17-0574. View

10.

Zhao J, Lin G, Zhuo M, Fan Z, Miao L, Chen L . Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib. Lung Cancer. 2019; 141:114-118. PMC: 7961300. DOI: 10.1016/j.lungcan.2019.10.021. View

11.

Henke E, Nandigama R, Ergun S . Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. Front Mol Biosci. 2020; 6:160. PMC: 7025524. DOI: 10.3389/fmolb.2019.00160. View

12.

Levantini E, Maroni G, Del Re M, Tenen D . EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022; 85:253-275. DOI: 10.1016/j.semcancer.2022.04.002. View

13.

Ercan D, Choi H, Yun C, Capelletti M, Xie T, Eck M . EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clin Cancer Res. 2015; 21(17):3913-23. PMC: 4791951. DOI: 10.1158/1078-0432.CCR-14-2789. View

14.

Eberle-Singh J, Sagalovskiy I, Maurer H, Sastra S, Palermo C, Decker A . Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2019; 25(18):5548-5560. DOI: 10.1158/1078-0432.CCR-18-3281. View

15.

Chen E, Tan C, Kou Y, Duan Q, Wang Z, Meirelles G . Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013; 14:128. PMC: 3637064. DOI: 10.1186/1471-2105-14-128. View

16.

Chen H, Albergante L, Hsu J, Lareau C, Lo Bosco G, Guan J . Single-cell trajectories reconstruction, exploration and mapping of omics data with STREAM. Nat Commun. 2019; 10(1):1903. PMC: 6478907. DOI: 10.1038/s41467-019-09670-4. View

17.

Girard N . Optimizing outcomes and treatment sequences in mutation-positive non-small-cell lung cancer: recent updates. Future Oncol. 2019; 15(25):2983-2997. DOI: 10.2217/fon-2019-0400. View

18.

Liu S, Liu Z, Shang A, Xun J, Lv Z, Zhou S . CD44 is a potential immunotherapeutic target and affects macrophage infiltration leading to poor prognosis. Sci Rep. 2023; 13(1):9657. PMC: 10267145. DOI: 10.1038/s41598-023-33915-4. View

19.

Gajewski T, Meng Y, Harlin H . Immune suppression in the tumor microenvironment. J Immunother. 2006; 29(3):233-40. DOI: 10.1097/01.cji.0000199193.29048.56. View

20.

Storti B, Civita S, Faraci P, Maroni G, Krishnan I, Levantini E . Fluorescence imaging of biochemical relationship between ubiquitinated histone 2A and Polycomb complex protein BMI1. Biophys Chem. 2019; 253:106225. DOI: 10.1016/j.bpc.2019.106225. View